Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies

Area of Science:

• Medicinal Chemistry
• Enzyme Inhibition
• Neuroscience

Background:

• Monoamine oxidase (MAO) enzymes are crucial targets for treating neurological disorders.
• Developing selective inhibitors for MAO-A and MAO-B isoforms is essential for therapeutic efficacy and minimizing side effects.
• Pyrazoline derivatives represent a promising scaffold for novel enzyme inhibitor development.

Purpose of the Study:

• To synthesize and evaluate a series of pyrazoline derivatives for their inhibitory activity against human MAO (hMAO) isoforms.
• To determine the structure-activity relationships (SAR) of these derivatives concerning hMAO-A and hMAO-B selectivity.
• To identify potent and selective hMAO inhibitors for potential therapeutic applications.

Main Methods:

• Synthesis of twenty-two pyrazoline derivatives.
• In vitro enzymatic assays to determine inhibitory activity against hMAO-A and hMAO-B.
• Calculation of selectivity indices (SI) to assess isoform preference.

Main Results:

• Twelve pyrazoline derivatives with unsubstituted ring A and substituted ring C (compounds 5-16) demonstrated potent inhibition of hMAO-A (SI in the order of 10^3–10^4).
• Ten derivatives with unsubstituted ring A and without ring C (compounds 21-30) showed varied selectivity: eight selective for hMAO-A, one for hMAO-B (compound 22), and one non-selective (compound 27).
• The presence of ring C significantly enhanced potency and selectivity for hMAO-A, whereas its absence reduced both potency and selectivity for both isoforms.

Conclusions:

• Pyrazoline derivatives are effective inhibitors of human monoamine oxidase.
• Substitution pattern, particularly the presence and nature of ring C, critically influences hMAO isoform selectivity and potency.
• These findings provide a basis for designing novel, selective hMAO inhibitors with therapeutic potential.